Abstract 2928
Background
The ARQ197-215 study randomized patients (pts) to tivantinib or placebo and pre-specified efficacy analyses indicated the predictive value of MET expression as a marker of benefit from tivantinib for second-line treatment of hepatocellular carcinoma (HCC). The aim of the current analysis was to evaluate in the ARQ197-215 cohort the neutrophil-to-lymphocyte ratio (NLR), which is thought to be a prognostic factor associated with clinical outcomes in several solid tumours.
Methods
A post hoc exploratory analysis was carried out on 98 ARQ197-215 pts with available absolute neutrophil count and absolute lymphocyte count, and preserved liver function. The cut-off used to define a high versus low NLR was the predefined value of 3.0, which corresponds to the median value. The effect of NLR was estimated with respect to overall survival (OS) and time to progression (TTP).
Results
No association was detected between the NLR and other known prognostic factors, including portal vein thrombosis (p = 0.671), MET expression (p = 0.552), alpha-fetoprotein levels (p = 0.837), and distant metastases (p = 0.521). In univariate analysis, compared with low NLR, a high NLR was associated with a hazard ratio (HR) for OS of 1.58 [95% confidence interval: 1.01; 2.47; p = 0.046]. Also, in multivariate analysis, the NLR and portal vein thrombosis remained independent prognostic factors for OS within the entire cohort. Median OS was 7.8 months versus 5.1 months for patients with NLR
Conclusions
Baseline NLR is a readily available and inexpensive prognostic biomarker in pts with advanced/metastatic HCC who are candidate for second-line treatments. This effect was independent of other known prognostic factors.
Clinical trial identification
NCT00988741
Legal entity responsible for the study
Humanitas Clinical and Research Center
Funding
ArQule Daiichi-Sankyo
Disclosure
G. Abbadessa: Employment - ArQule Stock and Other Ownership Interests - ArQule; Biogen Idec.
D. Shuster: Employment - Daiichi Sankyo.
M.E. Lamar: Employment - ArQule Stock and Other Ownership Interests – ArQule.
B. Schwartz: Employment - ArQule Leadership - ArQule Stock and Other Ownership Interests – ArQule.
A. Santoro: Consulting or Advisory Role - Amgen; ArQule; Celgene; Roche; Takeda.
L. Rimassa: Consulting or Advisory Role - Lilly; Merck Serono Travel, Accommodations, Expenses – ArQule.
All other authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract